12:00 AM
 | 
Nov 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Bococizumab: Phase III started

Pfizer disclosed in its 3Q13 earnings that it began the double-blind, placebo-controlled U.S. Phase III SPIRE-HR trial to evaluate 150 mg subcutaneous bococizumab every 2 weeks for 18 months in about...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >